Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody

Good pharmacokinetic (PK) behavior is a key prerequisite for sufficient efficacy of therapeutic monoclonal antibodies (mAbs). Fc glycosylation is a critical quality attribute (CQA) of mAbs, due to its impact on stability and effector functions. However, the effects of various IgG Fc glycoforms on an...

Descripción completa

Detalles Bibliográficos
Autores principales: Falck, David, Thomann, Marco, Lechmann, Martin, Koeleman, Carolien A. M., Malik, Sebastian, Jany, Cordula, Wuhrer, Manfred, Reusch, Dietmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781607/
https://www.ncbi.nlm.nih.gov/pubmed/33382957
http://dx.doi.org/10.1080/19420862.2020.1865596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781607/
https://www.ncbi.nlm.nih.gov/pubmed/33382957
http://dx.doi.org/10.1080/19420862.2020.1865596

Ejemplares similares